Clear Search

Showing 2 results for “patient-reported outcomes” published 2023.

July 2023

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus

J Rheumatol. 2023 Jun 15:jrheum.2023-0060 DOI: 10.3899/jrheum.2023-0060

An analysis of the California Lupus Epidemiology Study cohort demonstrated that more than a quarter of participants reported at least one medication cost concern, which was associated with worse patient-reported outcomes. These results reveal a potentially modifiable risk factor for poor outcomes rooted in the unaffordability of lupus care.

more…

June 2023

Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial

Arthritis Rheumatol. 2023;75(11):1983–93 doi: 10.1002/art.42557.

This phase II study of BI 655064 in patients with active LN did not meet the primary endpoint of CRR at Week 52, however, post-hoc analyses suggest a potential benefit of BI 655064 180 mg in patients with active LN.

more…